FindTrial
Sign In

Effects of cell therapy with mesenchymal stem cells and platelet-rich plasma in the treatment of knee osteoarthritis

Effects of cell therapy with mesenchymal stem cells from adipose tissue and platelet-rich plasma in the treatment of osteoartrite that was not responsive to drug treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2fr526n
Enrollment
Unknown
Registered
2021-11-16
Start date
2018-06-29
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee

Interventions

In this clinical, retrospective and uncontrolled study, a total of 26 patients who no longer responded to any drug intervention proposed by the Orthopedics team for at least 6 months participated. The
E02.095.147

Sponsors

Universidade Federal de Mato Grosso do Sul
Lead Sponsor
Universidade Federal de Mato Grosso do Sul
Collaborator

Eligibility

Age
No minimum to 80 Years

Inclusion criteria

Inclusion criteria: Volunteer individuals were included; diagnosed through physical assessment; be classified by imaging with osteoarthritis grade II to IV; who already had an indication for knee surgery; patients unresponsive to conservative treatment (physical and drug) commonly used in the Unified Health System (SUS) for at least 6 months.

Exclusion criteria

Exclusion criteria: Individuals with extreme deformities of the knee joint were excluded; who reported having hemophilia, anemia, gastrointestinal diseases, cancer, thyroid, liver, and previous nephrological disorders and HIV; patients who were chronically using immunosuppressive and anticoagulant drugs.

Design outcomes

Primary

MeasureTime frame
The use of mesenchymal stem cells in conjunction with platelet-rich plasma for the treatment of osteoarthritis is the most effective intervention when compared to the currently proposed conventional surgical treatment. Joint inflammation was assessed by analyzing the synovial fluid of the treated joint, collection took place before surgery and after 6 months of cell application. Analysis was performed by flow cytometry with an inflammatory cytokine marker kit.—

Secondary

MeasureTime frame
The group that used the combination of mesenchymal stem cells and platelet-rich plasma in the treatment of osteoarthritis was the most effective in terms of reducing inflammatory cytokines and improving the quality of synovial fluid in the treated joint. Decreases of 40% in the cytokine IL 1b, 72% in IL 6, 50% in IL 8, 20% in IL 10, 29% in IL 12p70 and 46% in TNF were observed when compared to the initial state of treatment.—

Countries

Brazil

Contacts

Public ContactRodrigo Oliveira
rodrigo.olveira@ufms.br55 67 984346510

Outcome results

None listed

Source: REBEC (via WHO ICTRP)